CLINICAL STUDIES FOR P-SHOT PRP THERAPY

CLINICAL STUDIES ON PLATELET-RICH PLASMA (PRP) or The P-SHOT® ON ED

Aim: To conduct the first double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of PRP injections in patients with mild and moderate ED.

Results: At 6 months, a MCID was achieved by 20/29 (69%) patients in the PRP group compared to 7/26 (27%) in the placebo group. The risk difference between the two groups was 42% (95%CI: 18-66), P < 0.001 and the baseline-adjusted mean between-group-difference in the IIEF-EF score was 3.9 points (95%CI: 1.8-5.9). Similarly, a statistically significant difference of both the number of participants attaining a MCID and the IIEF-EF score was also observed at the 1- and 3-month evaluation between the two groups. Accordingly, patients receiving PRP were more satisfied with the treatment. No adverse events were observed during the study period.

Cellular Medicine Association Announces That Urologists from the University of Aristotle in Greece Demonstrate That The P-Shot® Helps Men with Erectile Dysfunction

FAIRHOPE, Ala., June 14, 2021 /PRNewswire/ — Sixty men volunteered to have their penis injected with their own blood by eight urologists from Aristotle University in Greece; the results—a double-blind, randomized, placebo-controlled clinical trial published in the May 2021 issue of the Journal of Sexual Medicine—showed that “Platelet-Rich Plasma (PRP) Improves Erectile Function.”

Scroll to top